Table 3.
Dosimetric data evaluating LGE
| Factor (mean (range)) | All patients (N = 28) | No LGE (N = 19) | LGE (N = 9) | p-value |
|---|---|---|---|---|
| Dmax Heart EQD2 (Gy) | 50.9 (6.2–108.0) | 46.1 (6.2–82.6) | 60.8 (40.8–108.0) | 0.16 |
| Dmean Heart EQD2 (Gy) | 8.2 (1.0–35.7) | 8.8 (1.0–35.7) | 6.8 (1.8–21.8) | 0.57 |
| Dmax LV EQD2 (Gy) | 34.0 (0.2–94.7) | 29.4 (0.2–74.7) | 43.8 (13.6–94.7) | 0.17 |
| Dmean LV EQD2 (Gy) | 8.2 (0.1–34.4) | 8.4 (0.1–30.0) | 7.6 (1.4–34.4) | 0.84 |
| Heart V5Gy (%) | 48.5 (10–97) | 49.3 (10–97) | 46.8 (13–96) | 0.85 |
| Heart V30Gy (%) | 10.8 (0–69) | 11.0 (0–66) | 10.5 (0–44) | 0.94 |
| Heart V40Gy (%) | 7.6 (0–66) | 8.1 (0–66) | 6.7 (0–33) | 0.83 |
| Heart V50Gy (%) | 5.1 (0–59) | 5.8 (0–59.0) | 3.4 (0–23) | 0.65 |
| LV V5Gy (%) | 40.1 (0–100) | 37.3 (0–100) | 45.1 (18.5–100) | 0.61 |
| LV V30Gy (%) | 10.7 (0–71.8) | 10.7 (0–65.1) | 10.7 (0–71.8) | 0.99 |
| LV V40Gy (%) | 7.7 (0–55.5) | 7.8 (0–55.5) | 7.4 (0–53.1) | 0.95 |
| LV V50Gy (%) | 5.1 (0–48.8) | 5.6 (0–48.8) | 4.3 (0–36.4) | 0.81 |
| T1 mapping values (ms) | 1009 (933–1117) | 997 (933–1067) | 1033 (967–1117) | 0.054 |
*Dmax maximum dose, Dmean mean dose, EQD2 equivalent dose in 2 Gy fractions, Gy Gray, LGE late gadolinium enhancement, LV left ventricle, ms milliseconds, Vx volume in % receiving ≥ dose x in Gy. P-values reported for significance testing among patients with and without LGE